Mark Mossler - Sep 18, 2023 Form 3 Insider Report for C4 Therapeutics, Inc. (CCCC)

Role
Chief Accounting Officer
Signature
/s/ Jolie M. Siegel, Attorney-in-Fact
Stock symbol
CCCC
Transactions as of
Sep 18, 2023
Transactions value $
$0
Form type
3
Date filed
9/19/2023, 07:20 PM
Next filing
Apr 10, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding CCCC Stock Option (Right to Buy) Sep 18, 2023 Common Stock 50.2K $2.83 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the shares underlying this option shall vest and become exercisable on June 21, 2024, with the remainder vesting in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service on each vesting date.

Remarks:

Exhibit 24 - Power of Attorney